

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662



Date: 15th May, 2026

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

Sub.: Press Release issued by Fredun Pharmaceuticals Limited

Dear Sir/ Madam,

Please find enclosed press release titled “**Fredun Pharmaceuticals Unveils Cellular Longevity Dedicated Platform ‘Daulcé!’**” issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records.

Thanking you,

Yours truly,

For **Fredun Pharmaceuticals Limited**

Fredun Nariman Medhora
Managing Director
DIN: 01745348





Fredun Pharmaceuticals Unveils Cellular Longevity Dedicated Platform ‘DaulcéL’

Strategic entry into cellular aging and preventive healthcare through clinically backed NAD+ science

Mumbai – May 15, 2026: – Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), has announced the launch of ‘DAULCÉL’, its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks another strategic step in Fredun’s expansion into innovation-led and future-focused healthcare segments.

DAULCÉL is positioned as a premium wellness platform centered on quality, innovation, and evolving consumer wellness needs. The brand is aimed at addressing the increasing global focus on vitality, wellness optimization, recovery-focused healthcare, and long-term healthy living through science-oriented wellness solutions.

The initiative complements Fredun Pharmaceuticals Limited’s existing pharmaceutical and healthcare capabilities while creating new opportunities within specialized wellness and longevity-driven categories. The launch also reflects the Company’s continued focus on building a diversified and future-ready healthcare portfolio.

Highlights

- First premium **NAD+** based wellness offerings introduced in **India’s** emerging longevity and cellular wellness segment
- Launch of premium wellness and longevity-focused brand ‘DAULCÉL’
- Strategic expansion into preventive and lifestyle-oriented healthcare
- Focused on wellness, vitality, and healthy aging solutions
- Science-oriented and innovation-driven brand approach
- Expansion into emerging and high-growth wellness categories
- Strengthening Fredun’s specialty healthcare and wellness portfolio
- Leveraging the Company’s formulation and healthcare expertise
- Focused on differentiated, quality-driven wellness offerings

DAULCÉL’s initial portfolio is designed around premium wellness solutions aligned with the growing demand for advanced wellness, cellular vitality, and healthy lifestyle management. The brand aims to combine innovation, quality-focused development, and consumer-centric healthcare experiences to establish a differentiated presence within the evolving wellness market.

With increasing awareness around preventive wellness and longevity-focused healthcare globally, Fredun Pharmaceuticals Limited believes DAULCÉL is well-positioned to address emerging opportunities in the premium wellness segment while supporting the Company’s long-term growth and diversification strategy.

Commenting on the development, Mr. Fredun Medhora, Managing Director, said: *“Daulcéel reflects our focus on building future ready healthcare capabilities. Preventive health and longevity are becoming increasingly relevant, and we see strong potential in delivering science driven solutions that address these needs in a meaningful way.”*

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

In the FY25, Fredun reported total revenues of ₹ 456 Cr, with an EBITDA of ₹ 55 Cr and a PAT of ₹ 21 Cr.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal - Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com